Iron metabolism in hemodialyzed patients - A story half told?

Archives of Medical Science

Volumn 10, Issue 6, 2014, Pages 1117-1122

  Malyszko, Jolanta ^a   Koc Zorawska, Ewa ^a   Levin Iaina, Nomy ^b   Slotki, Itzchak ^c   Matuszkiewicz Rowinska, Joanna ^d   Glowinska, Irena ^a   Malyszko, Jacek S ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^b SHEBA MEDICAL CENTER   (Israel)

^c SHAARE ZEDEK MEDICAL CENTER   (Israel)

^d MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

Anemia; Ferritin; Hemodialysis; Hepcidin; Inflammation; Iron metabolism; Non transferrin bound iron

Indexed keywords

ALKALINE PHOSPHATASE; ANTIANEMIC AGENT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CREATININE; FERRITIN; GLUCOSE; HEMOGLOBIN; HEMOJUVELIN; HEPCIDIN; INTERLEUKIN 6; IRON; LIPID; NON TRANSFERRIN BOUND IRON; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG; UREA;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD CELL COUNT; FEMALE; FERRITIN BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HEMODIALYSIS PATIENT; HUMAN; INFLAMMATION; IRON BINDING CAPACITY; IRON BLOOD LEVEL; IRON METABOLISM; LIPID BLOOD LEVEL; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; UREA BLOOD LEVEL;

EID: 84920040545     PISSN: 17341922     EISSN: 18969151     Source Type: Journal    
DOI: 10.5114/aoms.2014.47823     Document Type: Article

References (40)

1. Breuer W, Hershko C, Cabantchik ZI. The importance of non-transferrin iron in disorders of iron metabolism. Transfusion Sci 2000; 23: 185-92.
2. Cabantchik ZI, Breuer W, Zanninelli G, Cianciulli P. LPI-la-bile plasma iron in iron overload. Best Pract Res Clin Haematol 2005; 18: 277-87.
3. Driss F, Vrtovsnik F, Katsahian S, et al. Efects of intravenous polymaltose iron on oxidant stress and non-trans-ferrin-bound iron in hemodialysis patients. Nephron Clin Pract 2005; 99: c63-7.
4. Prakash M, Upadhya S, Prabhu R. Serum non-transferrin bound iron in hemodialysis patients not receiving intravenous iron. Clin Chim Acta 2005; 360: 194-8.
5. Espósito B P, Breuer W, Slotki I, Cabantchik ZI. Labile iron in parenteral iron formulations and its potential for generating plasma nontransferrin-bound iron in dialysis patients. Eur J Clin Invest 2002; 32 Suppl 1: 42-9.
6. Scheiber-Mojdehkar B, Lutzky B, Schaufer R, Sturm B, Goldenberg H. Non-transferrin-bound iron in the serum of hemodialysis patients who receive ferric sacharate: no correlation to peroxide generation. J Am Soc Nephrol 2004; 6: 1648-55.
7. Hershko C, Peto TEA. Non-transferrin plasma iron. Br J Haematol 1987; 66: 149-51.
8. Baker E, Morgan EH. Iron transport. In: Iron metabolism in health and disease. Brock JH, Halliday JW, Pippard MJ, Poowell LW (eds.). Saunders, London 1994; 63-96.
9. Gutteridge JMC, Rowely DA, Grifths E, Halliwell B. Low molecular-weight iron complexes and oxygen radical reactions in idiopathic hemochromatosis. Clin Sci 1995; 68: 463-7.
10. Kooistra M P, Kersting S, Gosriwatana I, Lu S, Hider RC, Marx JJM. Non transferrin-bound iron in plasma of hae-modialysis patients after intravenous iron saccharate infusion. Eur J Clin Invest 2002; 32 (Suppl. 1): 36.
11. Malyszko J, Głowińska I, Malyszko JS, Levin-Iaina N, Koc-Zorawska E, Mysliwiec M. Iron metabolism in kidney al-lograft recipients: still a mystery? Transplant Proc 2011; 43: 2973-5.
12. Przybylowski P, Malyszko J, Levin-Iaina N, Malyszko JS. Lack of non-transferrin-bound iron in heart transplant recipients. Transplant Proc 2011; 43: 3068-70.
13. Dresow B, Petersen D, Fischer R, Nielsen P. Non-trans-ferrin-bound iron in plasma following administration of oral iron drugs. Biometals 2008; 21: 273-6.
14. Wang WC, Ahmed N, Hanna M. Non-transferrin-bound iron in long-term transfusion in children with congenital anemias. J Pediatr 1986; 108: 552-7.
15. Małyszko J, Levin-Iaina N, Mys̈liwiec M, Przybyłowski P, Durlik M. Iron metabolism in solid-organ transplantation: how far are we from solving the mystery? Pol Arch Med Wewn 2012; 122: 504-11.
16. Detivaud L, Nemeth E, Boudjema K, et al. Hepcidin levels in humans are correlated with hepatic iron stores, hemoglobin levels and hepatic function. Blood 2005; 106: 746-8.
17. Aoki CA, Rossaro L, Ramsamooj RR, Brandhagen D, Burritt M F, Bowlus CL. Liver hepcidin mRNA corrrelates with iron stores, but not infammation, in patients with chronic hepatitis C. J Clin Gastroenterol 2005; 39: 71-4.
18. Brissot P, Wright TL, Ma WL, Weisiger RA. Efcient clearance of nontransferrin-bound iron by rat liver. Implications for hepatic iron loading in iron overload states. J Clin Invest 1985; 76: 1463-70.
19. Craven CM, Alexander J, Eldridge M, Kushner J P, Bernstein S, Kaplan J. Tissue distribution and clearance kinetics of non-transferrin-bound iron in the hypo-transferrinemic mouse: a rodent model for hemochro-matosis. Proc Natl Acad Sci USA 1987; 84: 3457-61.
20. Baker E, Baker SM, Morgan EH. Characterisation of non-transferrin-bound iron (ferric citrate) uptake by rat hepatocytes in culture. Biochim Biophys Acta 1998; 1380: 21-30.
21. Wright TL, Brissot P, Ma WL, Weisiger RA. Characterization of nontransferrin-bound iron clearance by rat liver. J Biol Chem 1986; 261: 10909-14.
22. Harrison-Findik DD, Klein E, Crist C, Evans J, Timchenko N, Gollan J. Ironmediated regulation of liver hepcidin expression in rats and mice is abolished by alcohol. Hepatology 2007; 46: 1979-85.
23. De Feo TM, Fargion S, Duca L, et al. Non-transferrin-bound iron in alcohol abusers. Alcohol Clin Exp Res 2001; 25: 1494-9.
24. Kalantar-Zadeh K, Lee GH, Miller JE, et al. Predictors of hyporesponsiveness to erythropoiesis-stimulating agents in hemodialysis patients. Am J Kidney Dis 2009; 53: 823-34.
25. Brancaccio D, Cozzolino M, Gallieni M. Hyperparathyroid-ism and anemia in uremic subjects: a combined therapeutic approach. J Am Soc Nephrol 2004; 15 (Suppl. 1): S21-4.
26. Rao DS, Shih MS, Mohini R. Efect of serum parathyroid hormone and bone marrow fbrosis on the response to erythropoietin in uremia. N Engl J Med 1993; 328: 171-5.
27. Lee DH, Liu DY, Jakobs DR, et al. Common presence of nontransferrin-bound iron among patients with type 2 diabetes. Diabetes Care 2006; 29: 1090-5.
28. Silva AM, Hider RC. Infuence of non-enzymatic posttranslation modifcations on the ability of human serum albumin to bind iron. Implications for non-transfer-rin-bound iron speciation. Biochim Biophys Acta 2009; 1794: 1449-58.
29. Breuer W, Ghoti H, Shattat A, et al. Non-transferrin bound iron in Thalassemia: diferential detection of redox active forms in children and older patients. Am J Hematol 2012; 87: 55-61.
30. Sulieman M, Asleh R, Cabantchik ZI, et al. Serum che-latable redox-active iron is an independent predictor of mortality after myocardial infarction in individuals with diabetes. Diabetes Care 2004; 27: 2730-2.
31. Athyros VG, Hatzitolios AI, Karagiannis A, et al. IMproving the imPlemEntation of cuRrent guidelines for the mAnagement of major coronary hearT disease rIsk factors by multifactorial interVEntion. The IMPERATIVE renal analysis. Arch Med Sci 2011; 7: 984-92.
32. Aronow WS. Editorial on management of diabetes mel-litus with coronary artery disease. Arch Med Sci 2011; 7: 928-30.
33. Meyers DG. The iron hypothesis-does iron cause atherosclerosis? Clin Cardiol 1996; 19: 925-9.
34. Coelho M, Oliveira T, Fernandes R. Biochemistry of adipose tissue: an endocrine organ. Arch Med Sci 2013; 9: 191-200.
35. Franczyk-Skóra B, Gluba A, Banach M, Rysz J. Treatment of non-ST-elevation myocardial infarction and ST-eleva-tion myocardial infarction in patients with chronic kidney disease. Arch Med Sci 2013; 9: 1019-27.
36. Salonen JT, Nyyssonen K, Korpela H, Tuomilehto J, Sep-panen R, Salonen R. High stored iron levels are associated with excess risk of myocardial infarction in eastern Finnish men. Circulation 1992; 86: 803-8.
37. Sturm B, Goldenberg H, Scheiber-Mojdehkar B. Transient increase of the labile iron pool in HepG2 cells by intravenous iron preparations. Eur J Biochem 2003; 270: 3731-8.
38. Malyszko J, Malyszko JS, Mysliwiec M. Serum prohepci-din and hepcidin in hemodialyzed patients undergoing iron therapy. Kidney Blood Press Res 2009; 32: 235-8.
39. Charytan D, Fishbane S, Malyszko J, McCullough PA, Goldsmith D. Cardiorenal syndrome and the role of the bone-mineral axis and anemia. Am J Kidney Dis in press.
40. Lin CJ, Chuang CK, Jayakumar T, et al. Serum p-cresyl sulfate predicts cardiovascular disease and mortality in elderly hemodialysis patients. Arch Med Sci 2013; 9: 662-8.